Managing Schizophrenia with Medications

First-Line Treatment Strategy

Antipsychotic monotherapy should be the first-line pharmacological treatment for schizophrenia, with clozapine initiated after two failed monotherapy trials with other antipsychotics, as recommended by the American Psychiatric Association 1, 2
Assess response after 4-6 weeks of treatment at an adequate dose, with a moderate strength of evidence 3

Before starting antipsychotic treatment, obtain baseline measurements: BMI, waist circumference, blood pressure, blood glucose, lipids, prolactin, liver function tests, electrolytes, complete blood count, and electrocardiogram, as recommended by the National Institute for Health and Care Excellence 2
Monitor fasting glucose 4 weeks after initiation, with a high strength of evidence 2
Check BMI, waist circumference, and blood pressure weekly for 6 weeks, with a moderate strength of evidence 2
Repeat all measurements after 3 months of treatment and annually thereafter, with a moderate strength of evidence 2

If inadequate response after 4-6 weeks at an adequate dose but good tolerability, consider dose increase, with a low strength of evidence 3
After two failed adequate trials with different antipsychotics, initiate clozapine, as recommended by the American Psychiatric Association 1, 4
For treatment-resistant cases where clozapine is contraindicated or ineffective, consider antipsychotic polypharmacy, with a low strength of evidence 1, 5

Most patients (70%) require long-term, often lifetime medication to control symptoms, with a high strength of evidence 1, 5
Consider long-acting injectable antipsychotics if medication adherence is a concern, with a moderate strength of evidence 2

Only consider antipsychotic polypharmacy after failed trials of adequate dose and duration of monotherapy, including clozapine, with a low strength of evidence 1, 5
Combining aripiprazole with clozapine may be effective in reducing treatment side effects or residual symptoms, with a low strength of evidence 1, 5
Antipsychotic polypharmacy may increase side effects compared to monotherapy, with a moderate strength of evidence 1, 5

For akathisia, consider dose reduction or switching to quetiapine or olanzapine; alternatively, adjunctive propranolol (10-30 mg two to three times daily) may help, with a moderate strength of evidence 2
For metabolic side effects, consider switching to an antipsychotic with a more benign metabolic profile, adjunctive metformin, or GLP-1 receptor agonist, with a moderate strength of evidence 2
For hyperprolactinemia, consider switching to a D2 partial agonist or adding low-dose aripiprazole, with a moderate strength of evidence 2

For patients with comorbid substance use disorders, consider integrated treatment with specialist substance use disorder services, with a moderate strength of evidence 2

Generic first-generation antipsychotics, such as fluphenazine, are typically the least expensive options, according to the American Academy of Child and Adolescent Psychiatry 6, 7

Antipsychotic monotherapy should be prioritized over polypharmacy to reduce overall medication costs and minimize side effects, as recommended by the guideline society, with a strength of evidence level of high 8, 9
Combining lower doses of two less expensive antipsychotics can be equally effective as a higher dose of a single agent but at lower cost, with a moderate strength of evidence 10

Long-acting injectable antipsychotics may be cost-effective in the long run for patients with adherence issues by reducing hospitalization rates, with a low to moderate strength of evidence 11
Clozapine may be cost-effective for treatment-resistant schizophrenia by reducing hospitalization rates and improving outcomes, with a moderate strength of evidence 11, 12

Neglecting medication adherence issues can lead to ineffective treatment, even with affordable medications, with a high strength of evidence 9, 11